Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent as it selectively kills tumor cells but spares normal cells. Resistance to TRAIL by tumor cells limits its therapeutic use. We have previously shown that protein kinase C-e (PKCe) acts as an antiapoptotic protein in MCF-7 breast cancer cells. In the present study, we have investigated the mechanism(s) by which PKCe contributes to TRAIL resistance. Overexpression of PKCe inhibited caspase-8 and -9 activation, release of mitochondrial cytochrome c and cell death induced by TRAIL, but did not interfere with the recruitment of caspase-8 to the death-inducing signaling complex. Knockdown/inhibition of PKCe resulted in enhanced sensitivity to TRAIL. The level of Bcl-2 was increased and Bid was decreased by PKCe at both the protein and mRNA level but PKCe had no effect on Bax. Knockdown of Bcl-2 by siRNA reversed TRAIL resistance in PKCe-overexpressing cells, whereas depletion of Bid contributed to TRAIL resistance in MCF-7 cells. A decrease in Bid content was also associated with inhibition of TRAIL-induced caspase-8 activation. Furthermore, PKCe depletion or overexpression of DN-PKCe was associated with a decrease in Bcl-2 protein level. Thus, our results suggest that PKCe acts upstream of mitochondria and mediates TRAIL resistance via both Bcl-2 and Bid in MCF-7 cells.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a member of the tumor necrosis factor-a (TNF) superfamily, induces apoptosis in a variety of tumor cells with minimal toxicity to normal cells. 1 Thus, TRAIL is particularly valuable for cancer therapy. Resistance to TRAIL-mediated apoptosis by tumor cells, however, limits its therapeutic use. 2, 3 An understanding of the mechanism(s) of TRAIL resistance is essential to improve its application in cancer therapy.
TRAIL-mediated apoptosis involves ligand-dependent trimerization of TRAIL receptors DR4 or DR5, and the recruitment and activation of the death-inducing signaling complex (DISC) composed of Fas-associated death domain (FADD) and initiator procaspase-8. [4] [5] [6] Active caspase-8 subsequently cleaves and activates the effector caspase-3 and -7, ultimately resulting in apoptosis. 4, 5 Depending on the cell type, TRAIL can also amplify cell death through the mitochondrial pathway. 7 Cross-talk between the receptormediated pathway and mitochondria occurs when active caspase-8 cleaves Bid and the truncated Bid translocates to the mitochondria causing activation of Bax/Bak, release of cytochrome c and activation of caspases. [8] [9] [10] [11] Downregulation/mutations in caspase-8 or increased expression of FLIP can contribute to TRAIL resistance. 3, [12] [13] [14] [15] The presence of antiapoptotic proteins, such as Akt or Bcl-2 family members can also contribute to TRAIL resistance by affecting either the extrinsic or the intrinsic cell death pathway. 2, 10, [15] [16] [17] [18] Protein kinase C (PKC), a family of phospholipid-dependent serine/threonine kinases, is emerging as a critical regulator of cellular responses to TRAIL. 12, 14, [18] [19] [20] [21] [22] [23] [24] The PKC family consists of 11 isoforms that are classified as conventional (a, b1, b2 and g), novel (d, e, Z and y) or atypical (z and i/l). 25 PKCs are involved in the regulation of cell proliferation, differentiation as well as cell death. 26 PKCe is the only PKC isoform that has been reported to have oncogenic potential. 27, 28 There is also considerable evidence that PKCe acts as an antiapoptotic protein. 23, 29, 30 Activation of PKC was shown to protect against TRAILinduced apoptosis in several cell lines, including cervical cancer, multiple myeloma, glioma and breast cancer. 19, 20, 22, 23 There are conflicting reports as to the mechanisms by which PKC exerts its protective effect. In cervical cancer HeLa cells, PKC activation hindered apical events in the TRAIL receptor-mediated pathway by interfering with FADD recruitment to the DISC. 20 PKC inhibitors inhibited FLIP and cIAP-2 expression in multiple myeloma cells. 12, 14 In melanoma and breast cancer MCF-7 cells, PKC acted upstream of mitochondria but downstream of caspase-8 and Bid. 19, 22 In the latter study, the effect of phorbol myristic acetate (PMA) was examined but the contribution of a specific PKC isoform was not tested. The mechanism of TRAIL resistance may vary depending on the PKC isozyme. 14, 18, 19, 24, 31 PKCe has been implicated in inhibiting TRAIL-induced apoptosis in glioma and melanoma cells. 18, 19, 23 Increased levels and activity of PKCe were associated with TRAIL resistance, 19 and overexpression of PKCe inhibited TRAILinduced apoptosis in these cells. 18, 23 It has been reported that cellular susceptibility to TRAIL cannot be explained by the status of TRAIL receptor expression but does correlate with PKCe level. 23 Furthermore, PKCe overexpression did not modify the cell surface expression of TRAIL receptors in erythromyeloid cell lines. 21 It has been reported that mitochondria constitute an important target in overcoming inherent resistance to TRAIL. 2, 3, 10, 16, 19, 22, 32 However, PKCe did not affect Bcl-2 and Bax in glioma cells. 18 Thus, the mechanisms underlying the protective effect of PKCe and its regulation of components of the mitochondrial pathway in TRAIL-induced cell death are incompletely understood.
We have previously reported that PKCe protects MCF-7 breast cancer cells against receptor-initiated apoptosis. 30 In this study, we have examined the mechanism(s) of the antiapoptotic effect of PKCe in TRAIL-induced cell death. We report for the first time that PKCe inhibited TRAIL-mediated apoptosis by simultaneously increasing Bcl-2 and decreasing Bid expression in MCF-7 cells. Additionally, a decrease in Bid was associated with inhibition of TRAIL-induced caspase-8 activation. These results explain how PKCe could inhibit TRAIL-induced apoptosis by acting upstream of mitochondria at the level of Bid and Bcl-2.
Results
Overexpression of PKCe delays TRAIL-induced cell death. We have previously shown that PKCe protects cells against TNF-induced cell death in MCF-7 cells. 30 We determined whether PKCe overexpression would exert a protective effect against TRAIL-induced apoptosis. MCF-7 cells overexpressing PKCe (MCF-7/PKCe) or vectortransfected control cells (MCF-7/Neo) were treated with different concentrations of TRAIL, and cell viability was determined by the 3-4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide (MTT) assay. Figure 1a revealed that the IC 50 of TRAIL for MCF-7/Neo cells (0.027 nM) was almost eightfold less than MCF-7/PKCe cells (0.16 nM). The IC 50 of TRAIL for MCF-7/Neo cells was equivalent to untransfected MCF-7 cells (0.021 nM, data not shown). As MCF-7 cells transfected with the empty vector can control for any nonspecific effect associated with transfection and G418 selection, we primarily used MCF-7/Neo cells instead of MCF-7 cells for comparison with MCF-7/PKCe cells.
MCF-7 cells lack caspase-3 and therefore they do not undergo DNA fragmentation or exhibit characteristic morphological features of apoptosis, such as chromatin condensation. 33 Poly(ADP-ribose) polymerase (PARP) is a substrate for both caspase-3 and -7, and the cleavage of full-length 116-kDa PARP to the 85-kDa cleaved form is a convenient way to monitor cell death. Figure 1b shows that TRAIL induced a concentration-dependent increase in PARP cleavage; the 85-kDa cleavage product of PARP was evident when MCF-7/Neo cells were treated with 0.03 nM TRAIL. We have tested two different stable clones of MCF-7 cells expressing PKCe and both clones exhibited resistance to TRAIL-induced cell death. Unless otherwise mentioned, we have used clone 1 in all subsequent experiments and these cells are designated as MCF-7/PKCe. Overexpression of PKCe decreased TRAILinduced PARP cleavage and a 10-fold higher concentration of TRAIL was necessary to cause equivalent PARP cleavage in MCF-7/PKCe cells. In contrast, 0.01 nM TRAIL was sufficient to induce PARP cleavage in MCF-7 cells expressing dominant-negative PKCe.
We also examined the effect of PKC overexpression on the time course of PARP cleavage. As shown in Figure 1c , PARP cleavage in MCF-7/Neo cells was evident at 6 h of treatment with TRAIL, whereas MCF-7/PKCe cells exhibited a delayed response to TRAIL, with PARP cleavage evident at 18 h of treatment. As prolonged treatment with TRAIL may cause further cleavage of PARP, it is sometime difficult to demonstrate a time-dependent increase in cleaved PARP. The levels of full-length PARP in TRAIL-treated MCF-7/PKCe cells were greater compared to MCF-7/Neo cells. Thus, overexpression of PKCe in MCF-7 cells delayed TRAILinduced cell death.
We also examined the effect of PKCe overexpression on the clonogenic survival. As shown in Figure 1d , treatment of vector-transfected cells with 0.1 nM TRAIL caused a substantial decrease in colony formation, such that 37 and 10% colonies survived when MCF-7/Neo cells were treated with TRAIL for 10 and 20 h, respectively. In contrast, similar treatment of MCF-7/PKCe with TRAIL decreased clonogenic survival only to 76 and 67%. These results suggest that PKCe protected MCF-7 cells from loss of clonogenic survival induced by TRAIL.
Overexpression of PKCe does not affect TRAIL receptor expression and caspase-8 recruitment to the DISC. As binding of TRAIL to its receptors causes recruitment of FADD and caspase-8 to form DISC resulting in activation of caspase-8, we examined if overexpression of PKCe interferes with the recruitment of caspase-8 to the DISC. Figure 2 shows that PKCe overexpression had no effect on the levels of DR4 and DR5. In addition, the abundance of FADD and caspase-8 associated with the DISC did not decrease by PKCe overexpression. A slight decrease in procaspase-8 in the DISC of MCF-7/Neo cells compared to MCF-7/PKCe could be due to processing of procaspase-8 during 30 min incubation with 500 ng/ml TRAIL to generate the cleaved fragment. These results suggest that a decrease in caspase-8 recruitment to the DISC was not responsible for TRAIL resistance of MCF-7/PKCe cells.
Overexpression of PKCe inhibits TRAIL-induced caspase activation. Although TRAIL primarily acts through the receptor-initiated pathway, it can also amplify cell death through the mitochondrial pathway. 7 We therefore examined the effect of PKCe on TRAIL-induced activation of apical caspase-8 and -9 of the extrinsic and intrinsic pathway, respectively ( Figure 3) . Treatment of MCF-7/Neo cells with TRAIL caused a concentration-dependent increase in processing of both procaspase-8 and -9. MCF-7 cells do not express functional caspase-3, but the activation of effector caspase-7 and -6 was increased by TRAIL treatment. PKCe overexpression attenuated TRAIL-induced activation of both apical caspase-8 and -9, as well as downstream effector caspase-6 and -7 ( Figure 3 ). Thus, PKCe not only affects the extrinsic cell death pathway but also suppresses signaling through the intrinsic or mitochondrial cell death pathway.
Neo PKC The level of Apaf-1, a cytosolic protein, was not affected by TRAIL treatment. Cytochrome oxidase subunit 2, a mitochondrial marker, was detected only in the mitochondrial fraction. These results suggest that PKCe overexpression inhibits the mitochondrial cell death pathway by inhibiting release of cytochrome c from the mitochondria.
Overexpression of PKCe upregulates Bcl-2 and downregulates Bid expression. As Bcl-2 family proteins regulate the mitochondrial cell death pathway, we compared levels of the Bcl-2 family proteins in MCF-7/Neo and MCF-7/ PKCe cells. As shown in Figure 5a , the level of Bcl-2 was increased whereas the level of Bid was decreased in two stable clones of MCF-7 cells overexpressing PKCe compared to MCF-7/Neo cells. Based on densitometric scanning of several independent experiments, there was a 2.5-fold increase in Bcl-2 (Po0.05) and a 3.3-fold decrease in Bid (Po0.05) in MCF-7/PKCe cells compared to MCF-7/Neo cells (Figure 5b ). Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of RNA isolated from these cell lines also revealed an increase in Bcl-2 and a decrease in Bid mRNA in MCF-7/PKCe cells (Figure 5c ). Similar results were obtained when two different primers were used during RT-PCR. The proteasome inhibitor MG132 had no effect on the decrease in Bid in MCF-7/PKCe cells (data not shown). These results suggest that PKCe regulates Bid and Bcl-2 at the level of transcription. However, levels of Bax mRNA and protein were equivalent in both cell lines. Thus, an increase in the ratio of antiapoptotic Bcl-2 to proapoptotic Bid may contribute to TRAIL resistance in MCF-7/PKCe cells. PKCe overexpression did not decrease the levels of other antiapoptotic proteins, such as X-linked inhibitor of apoptosis (XIAP) or c-FLIP (Figure 5d ).
Depletion of Bid inhibits TRAIL-induced apoptosis in MCF-7 cells.
To determine the functional significance of Bid downregulation in MCF-7/PKCe cells, we overexpressed Bid in MCF-7/PKCe cells. The transfection efficiency of Bid plasmid in MCF-7/PKCe was low (7-8%) and overexpression of Bid in MCF-7/PKCe cells by itself caused cell death ( Figure 6 ). Therefore, we were unable to isolate stable clones. Nevertheless, these results suggest that overexpression of Bid can reverse antiapoptotic effect of PKCe. We then depleted Bid using siRNA and determined cell death in response to TRAIL. Treatment with TRAIL also resulted in the cleavage of Bid and the truncated Bid (t-Bid) was visible in TRAIL-treated MCF-7 (Figure 7b ) or MCF-7/Neo cells (Figure 7c ). Interestingly, depletion of Bid by siRNA was associated with a decrease in the cleavage of full-length Bid (Figure 7b and c) . As Bid is cleaved by caspase-8, we examined the effect of Bid knockdown on caspase-8 processing. Figure 7b shows that depletion of Bid inhibited processing of not only procaspase-9 but also of procaspase-8.
Depletion of Bcl-2 potentiates TRAIL-induced apoptosis in MCF-7 cells. We also examined the consequence of Knockdown of PKCe increases TRAIL sensitivity. To further examine the link between Bcl-2, Bid and the antiapoptotic function of PKCe, we depleted PKCe by siRNA. Figure 10 shows that knockdown of PKCe by siRNA enhanced cellular sensitivity to TRAIL as determined by activation of caspase-8 and -9, PARP cleavage ( Figure 10a ) and Annexin V dye binding assay (Figure 10b ). Although TRAIL (0.01 nM) had little effect on cell death in untransfected and control siRNA-transfected MCF-7 cells, it caused approximately 70% cell death in PKCe-depleted cells (Figure 10b ). Knockdown of PKCe decreased Bcl-2 level (Figure 10c ). Based on densitometric scanning of three independent experiments, PKCe depletion was associated with a 2.2-fold decrease in Bcl-2. PKCe knockdown caused only a modest increase in Bid (Figure 10c ). Expression of dominant-negative PKCe also caused a similar decrease in Bcl-2 and an increase in Bid (Figure 10d ). Thus, although the levels of both Bcl-2 and Bid are important determinants of PKCe-mediated TRAIL resistance, decrease in Bcl-2 may be primarily responsible for TRAIL sensitization in PKCedepleted cells.
Discussion
The ability of TRAIL to kill cancer cells is counteracted by the presence of antiapoptotic proteins, contributing to TRAIL resistance. In the present study, we have investigated the mechanism(s) by which PKCe contributes to TRAIL resistance. Our results show that an increase in antiapoptotic Bcl-2 and a decrease in proapoptotic Bid were associated with PKCe-mediated TRAIL resistance in MCF-7 cells. There have been several reports that suggest that PKC acts upstream of the mitochondrial pathway to regulate cell death by TRAIL, although the site of action of PKCe in the cell death pathway is not well established. 18, 19, 22, 23 The mitochondrial cell death pathway is regulated by the interaction between pro-and antiapoptotic members of the Bcl-2 family. Several studies have implicated Bax as an important mediator of cellular responsiveness to TRAIL. 16, 34, 35 Bax-deficient colon cancer cells were resistant to TRAIL-induced apoptosis. 2 Bax, but not Bak, sensitized leukemic and prostate cancer cells to TRAIL. 35, 36 PKCe-deficient LNCaP cells were sensitive to PMA-induced apoptosis and forced expression of PKCe in these cells conferred resistance to PMA-mediated apoptosis via interaction with Bax. 34 We have shown that the levels of antiapoptotic Bcl-2 as well as proapoptotic Bid were regulated by PKCe in MCF-7 breast cancer cells, whereas PKCe had no effect on the level of Bax. It has been reported that EPOdriven upregulation of PKCe level renders differentiating erythroid cells resistant to TRAIL likely via Bcl-2 upregulation. 21 We have shown that overexpression of PKCe increased Bcl-2 not only at the protein level but also at the mRNA level. In addition, knockdown of PKCe by siRNA decreased Bcl-2 level. Furthermore, depletion of Bcl-2 by siRNA reversed the antiapoptotic effect of PKCe. Taken together, these results provide direct evidence that Bcl-2 is involved in the antiapoptotic function of PKCe in MCF-7 breast carcinoma cells. Depletion of Bcl-2 not only enhanced TRAILinduced activation of caspase-9 but also of caspase-8. As caspase-8 can also be cleaved by effector caspases, such as caspase-6, activation of caspase-8 could be a consequence of TRAIL-induced activation of caspase-9. Although MCF-7 cells do not express caspase-3, which is believed to cleave caspase-6, 37 TRAIL did induce processing of caspase-6 in MCF-7 cells and PKCe inhibited cleavage of procaspase-6.
It is generally believed that the antiapoptotic effect of PKCe occurs downstream of caspase-8 activation and Bid cleavage. 18, 19, 21, 22, 38 We also found that overexpression of PKCe did not alter the levels of TRAIL receptors or interfere with the recruitment of caspase-8 to the DISC. Overexpression of PKCe caused a decrease in Bid protein and mRNA in MCF-7 cells. Consequently, the level of truncated Bid in response to TRAIL treatment was also lower in PKCe-overexpressing cells. However, depletion of PKCe caused only a slight increase in Bid level. It is conceivable that although overexpression of PKCe represses Bid transcription, a decrease in constitutive level of PKCe had no effect on Bid expression. Alternatively, as Bid is cleaved when cells undergo apoptosis and depletion of PKCe alone induces cell death, it may be difficult to demonstrate increase in Bid following depletion of PKCe. Consistent with this notion, we have found that overexpression of Bid not only induced cell death in PKCeoverexpressing cells (Figure 6 ), but also resulted in cleavage of Bid (data not shown). We do not know if forced expression of Bid results in mitochondrial localization causing release of cytochrome c and activation of caspases resulting in cleavage of Bid. In addition, knockdown of Bid by siRNA decreased TRAIL sensitivity in MCF-7 cells, suggesting the importance of Bid in regulating TRAIL sensitivity in these cells. Overexpression of PKCe in MCF-7 cells caused inhibition of caspase-8 and -9 processing in response to TRAIL. The effect of PKCe on caspase-8 activation may be a consequence of the decrease in Bid expression. We have shown that knockdown of Bid in fact inhibited TRAIL-induced cleavage of Bid and activation of caspase-8. Thus, Bid is not only a substrate for caspase-8 but it can also regulate its activation. We propose that in response to TRAIL, activation of caspase-8 results in cleavage of Bid and translocation of t-Bid to mitochondria, resulting in release of cytochrome c, activation of caspase-9 and cell death. This cross-talk drives more caspase-8 cleavage by a feed-forward mechanism. As the level of Bid is decreased by PKCe overexpression, the level of t-Bid generated by TRAIL-induced activation of casapse-8 is less in PKCe-overexpressing cells. As PKCe also induces antiapoptotic Bcl-2, the ratio of antiapoptotic and proapoptotic Bcl-2 family members is increased further. Inhibition of the mitochondrial cell death pathway results in a decrease in Bid cleavage and inhibition of TRAIL-induced caspase-8 activation.
TRAIL is a highly promising candidate for the treatment of cancer because it exhibits selective cytotoxicity to cancer cells. Some tumor cells, however, evade TRAIL-induced apoptosis owing to the presence of antiapoptotic proteins. It has been reported that tumor cells that overexpress PKCe are resistant to TRAIL. 19, 23 The elucidation of the mechanism of TRAIL resistance is highly significant for its effective application in the clinic. We provide direct evidence that both Bcl-2 and Bid are important for PKCe-mediated TRAIL resistance. Thus, Bcl-2 family proteins could be targeted to reverse TRAIL resistance in breast cancer cells.
Materials and Methods
Reagents. Human recombinant TRAIL and polyclonal antibody to caspase-8 were purchased from R&D systems (Minneapolis, MN, USA). Human recombinant FLAG-TRAIL, monoclonal antibody to anti-FLAG and polyclonal antibodies to DR4 and DR5 were obtained from Axxora LLC (San Diego, CA, USA). Monoclonal antibody to Bcl-2, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), c-FLIP and polyclonal antibody to PKCe were purchased from Santa Cruz Biotechnology, Cell culture and transfection. MCF-7 cells were maintained in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum and 2 mM glutamine and kept in a humidified incubator at 371C with 95% air and 5% CO 2 . MCF-7/Neo, MCF-7/PKCe and MCF-7/DN-PKCe cells were generated as described previously. 30 MCF-7/PKCe cells were co-transfected with either 2 mg of empty vector or Bid-pcDNA3.1 together with 2 mg SV40-b-gal plasmids using Fugene HD reagent (Roche Biomedicals) according to the manufacturer's instructions. Clonogenic assay. MCF-7/Neo or MCF-7/PKCe cells were seeded in 10-cm tissue culture dish and allowed to attach overnight. Cells were treated with or without 0.1 nM TRAIL for the indicated periods. Following incubation, the media were replaced with fresh media. Cells were then incubated in a humidified incubator at 371C and 5% CO 2 until there were at least 50 cells per colony in untreated cells. At the end of the incubation, cells were washed with phosphate-buffered saline (PBS) and incubated with a 0.25% crystal violet solution for 15 min. Colonies were counted using the colony-counting tool in the BioChemi System (UVP).
RT-PCR analysis. Total RNA was isolated using RNA STAT-60 from Tel-Test Inc, (Friendswood, TX, USA), as per the manufacturer's protocol and subjected to RT reaction using Promega (Madison, WI, USA) reverse transcriptase enzyme (ImProm-IIt). PCR amplifications were performed using the following primers: Bax, forward, Preparation of cytosolic and mitochondrial extracts. Following treatment with or without TRAIL, cells were collected, washed twice with PBS and subcellular fractionation was performed as described previously. 39 Immunoblot analysis. Equivalent amounts of protein from total cellular extracts were electrophoresed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred electrophoretically to polyvinylidene difluoride membrane. Immunoblot analyses were performed as described previously.
39
DISC analysis. Analysis of DISC formation was performed as described previously 40 with some modifications. Briefly, cells were treated with 500 ng/ml human recombinant soluble FLAG-tagged TRAIL and 1.5 mg/ml anti-FLAG monoclonal antibody (enhancer) for 30 min. Cells were lysed in 20 mM Tris-HCl, pH 7.4, 0.15 M NaCl, 1 mM EDTA, 1% TX-100, 0.5% NP-40, 25 mM bglycerophosphate, 10 mM NaF, 1.0 mM Na 3 VO 4 and protease inhibitor cocktail, and protein complexes were precipitated by incubation with protein A/G agarose. Beads were washed four times with immunoprecipitation buffer and denatured by boiling in Laemmli buffer containing b-mercaptoethanol. Proteins were separated by SDS-PAGE and Western blot analyses were performed.
Annexin V/PI-binding assay. Cells were treated with or without TRAIL. At the end of the incubation, both detached cells and attached cells were collected and washed with PBS. Cells were then stained with Annexin V-Alexa 488 conjugate and PI according to the manufacturer's protocol and analyzed using a flow cytometer (Coulter Epics). 
